Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Nyxoah S.A.NASDAQ: NYXH

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to €0

Q1 FY2026 stock-based compensation was €0, compared with €1.98M a year earlier. Trailing-twelve-month stock-based compensation was €887K.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 87.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near €0 or moves back toward the trailing-twelve-month quarterly average of €221.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0— QoQ
Last fiscal yearDec 2025
€0-100.0% YoY
LTMMar 2026
€887K-82.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -82.2% is the 9th highest of 10, against a peer median of -5.3%.
  • Stock-based compensation amounts to 5.4% of revenue for NYXH, versus a peer median of 7.4%.
NYXH Competitors
Stock-Based Compensation for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$15.02M USD-24.7%-4.8%52.0%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
OSUROraSure Technologies, Inc.LTM Mar 2026$11.45M USD-1.6%-90.4%10.1%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.42M USD+38.0%+88.2%1524.4%
STIMNeuronetics, Inc.LTM Mar 2026$5.4M USD-5.3%-7.8%3.6%
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M USD+16.7%-17.0%—
KRMDKORU Medical Systems, Inc.LTM Mar 2026$1.98M USD-24.3%-4.1%4.6%
NYXHNyxoah S.A.LTM Mar 2026€887K EUR-82.2%—5.4%
UTMDUtah Medical Products, Inc.LTM Mar 2026$411K USD+58.7%+26.8%1.1%
PREPrenetics Global LimitedLTM Mar 2026$141K USD-98.0%—0.1%
Peer median (excluding NYXH) —-5.3%-6.3%7.4%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.64M)(30.06M)(44.66M)(56.43M)(90.05M)
Depreciation & Amortization1.66M1.93M2.36M2.72M4.48M
Deferred Income Tax00000
Stock-Based Compensation1.27M2.7M2.61M3.97M0
Change in Working Capital(1.14M)86K(3.49M)2.96M5.37M
Accounts Receivables(2.52M)7K(1.54M)(751K)(2.14M)
Inventory(291K)(536K)(2.43M)(1.4M)55.98K
Accounts Payables00007.45M
Other Working Capital1.67M615K479K5.11M0
Other Non-Cash Items(2.49M)(3.42M)(1.6M)(2.44M)12.7M
Operating Cash Flow(25.34M)(28.76M)(44.78M)(49.23M)(67.5M)
Capital Expenditures(11.82M)(16.35M)(10.96M)(6.07M)(804.7K)
Acquisitions (Net)00003K
Purchases of Investments0(102.62M)(80.02M)(97.83M)(42.03M)
Sales of Investments028.91M120.68M85.31M71.97M
Other Investing Activities(10.35M)(15.35M)(6.15M)(2.64M)0
Investing Cash Flow(11.82M)(89.95M)32.01M(16.33M)26.17M
Debt Repayment(863K)(1.07M)(1.24M)8.48M21.19M
Common Stock Issued77.73M255K18.34M69.72M20.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(393K)(167K)(243K)(758K)(3.26M)
Financing Cash Flow76.47M(983K)16.86M77.44M38.79M
Effect of Forex Changes3.89M2.06M(369K)688K2.41M
Net Change in Cash43.21M(117.62M)3.72M12.58M(130.69K)
Free Cash Flow(37.15M)(45.11M)(55.74M)(55.3M)(68.3M)

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.